Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:04 am EST
Share
Ilsung Pharmaceuticals Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,398.34 million compared to KRW 1,045.25 million a year ago. Net income was KRW 4,481.53 million compared to KRW 3,283.48 million a year ago. Basic earnings per share from continuing operations was KRW 658 compared to KRW 431 a year ago. Basic earnings per share was KRW 658 compared to KRW 431 a year ago.
For the nine months, sales was KRW 3,979.88 million compared to KRW 3,490.91 million a year ago. Net income was KRW 18,763.28 million compared to KRW 103,718.98 million a year ago. Basic earnings per share from continuing operations was KRW 2,660 compared to KRW 13,870 a year ago. Basic earnings per share was KRW 2,660 compared to KRW 13,870 a year ago.
Ilsung IS Co Ltd, formerly Ilsung Pharmaceutical Co Ltd, is a Korea-based company mainly engaged in the pharmaceuticals manufacture and sale business. The Companyâs products consist of penicillin antibiotics, contrast mediums, digestive drugs, cardiovascular agents, antihistamines, anti-diabetics, bone disease drugs, analgesics, muscle relaxants, anesthetics, skin disease drugs, cardiovascular drugs, psychiatry drugs, antivirals, antipyretics and others. The Company distributes its products through wholesalers, hospitals, pharmacies and others. The Company also provides consignment production services.
ILSUNG IS CO., LTD. 
